ALMUDENA N.
- Country
- Spain
- Department
- Hematology
Research Overview
- Evaluation of Adverse Events, Pharmacokinetics, and Disease Activity of Oral ABBV-101 in Adult Patients with Select B-Cell Malignancies
- A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
Data & Insights
Has run more than one trial at 38 of 193 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the study and treatment of mature B cell malignancies, focusing on advancing therapeutic approaches for patients with hematological disorders.
- B-Cell Lymphoproliferative Disorders
- Blood Cancer Research
- Hematologic Malignancy Treatment
The investigator explores novel therapeutic agents targeting specific pathways in B-cell malignancies.
Targeted Therapy Development
Areas of focus include the investigation of targeted therapeutic approaches for blood cancers, with particular emphasis on B-cell specific treatments.
- Novel Agent Evaluation
- Treatment Innovation
- Therapeutic Response Assessment
The research encompasses evaluation of innovative compounds designed for hematologic cancers.
Clinical Applications
The investigator works on developing clinical applications for treating various forms of mature B-cell disorders.
- Treatment Protocol Development
- Patient Response Evaluation
- Clinical Outcome Assessment
Research efforts focus on translating therapeutic innovations into practical clinical applications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.